Samsung Bioepis and Teva expand partnership to up to six biosimilars

Samsung Bioepis and Teva signed a global license, development and commercialization agreement covering up to six biosimilar candidates. Two are confirmed: SB41 (referencing Fasenra) and SB44 (referencing Ilaris), with an option for four more. Bioepis handles development, regulatory registration and manufacturing, while Teva commercializes in the U.S., Europe and Canada.

• Agreement covers up to six biosimilars, with two confirmed: SB41 and SB44
• SB41 references Fasenra (benralizumab); SB44 references Ilaris (canakinumab)
• Samsung Bioepis handles development, regulatory registration and manufacturing
• Teva commercializes the products in the U.S., Europe and Canada